New Enterprise Associates, Inc. (NEA) is a leading venture capital and growth equity firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With approximately $11 billion in committed capital, NEA invests in information technology, healthcare and energy technology companies at all stages in a company's lifecycle, from seed stage through IPO. Since the firm's founding in 1978, NEA's experienced management team has invested in over 650 companies, of which more than 165 have gone public and more than 265 have been acquired. In the U.S., NEA has two offices in the Washington, D.C. metropolitan area and one in Menlo Park, California. In addition, New Enterprise Associates (India) Pvt. Ltd. has offices in Bangalore and Mumbai, India and New Enterprise Associates (Beijing), Ltd. has offices in Beijing and Shanghai, China.
Organized in 1973, Johnson & Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson & Johnson. JJDC makes private equity investments in venture funded health care companies. Portfolio companies include those in the fields of pharmaceuticals, biotechnology, medical devices, diagnostics and consumer products. JJDC also leads and manages internal investments in selected promising technologies.
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to building successful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Astellas Venture Management LLC is the corporate venture capital arm of Astellas Pharma Inc., a global pharmaceutical company headquartered in Japan, investing in emerging biotechnology companies dedicated to development of new therapeutics and new drug discovery platform technology. It is currently managing four funds of total $96.5M and is based in Menlo Park, California.
Fletcher Spaght Ventures, L.P. (FSV) is a venture capital firm investing in emerging growth healthcare and high technology companies. Fletcher Spaght invests as a lead investor and as a co-investor, collaborating and investing with other leading venture capital firms. As value added investors, it brings to bear the resources of it consulting division, Fletcher Spaght, Inc., established in 1983, which focuses on board-level pre-commercialization intelligence for start-ups, and market and due diligence assignments for larger corporations. FSV has two funds under management totaling $120M with investments nationwide.